This application is submitted on behalf of the AECC in order to request continued funding via the U10 mechanism as a main institutional member of the Eastern Cooperative Oncology Group (ECOG). Einstein faculty members play key scientific and administrative leadership roles in ECOG, and accrue a large number of minority subjects and women. The Einstein Cancer Center is an NCI-designated Cancer Center that has been continuously funded since 1971, and is currently funded until July 2012 (P30 CA13330). During the last five year funding period ending 4/30/09, Einstein and its affiliates accrued a total of 604 patients into cancer clinical trials via the ECOG mechanism, including 229 therapeutic accruals from the main institution. Moreover, 64% of all subjects enrolled at the main institution were minority subjects. Einstein faculty members have provided scientific leadership in the breast (J. Sparano), lung (R. Perez-Soler), leukemia (R. Gallagher, A. Verma), head/neck (M. Haigentz), thoracic surgery (S. Keller), and Gl (L. Rajdev) committees. Einstein-affiliated investigators have authored or co-authored 28 manuscripts and 69 abstracts related to ECOG studies, including publications that have influenced the standard of care for operable breast cancer (E1199 - NEJM, 2008) and influenced choice of the standard adjuvant chemotherapy for the ongoing adjuvant E5103 breast cancer trial. In addition, presentations at major scientific meetings have contributed to biomarker development in breast cancer, including oral presentations at the 2008 ASCO Breast Cancer Symposium, 2009 San Antonio Breast Cancer Symposium, and 2009 ASCO meeting. Furthermore, the APL Core Laboratory at Einstein (R. Gallagher) has supported ECOG's translational research, and the Einstein Center for Epigenomics (J. Greally) is positioned to play a major role in the next funding period. The principal investigator of this application (J. Sparano) also pays a key administrative role in ECOG as an Executive Committee member, Associate Chair for Disease and Modality Oriented Research, Vice- Chair of the Breast Committee, TAILORx study chair, and program chair for the annual ECOG Young Investigator's Symposium. Finally, the recent recruitment Dr. Steven Libutti will serve to expand the surgical oncology program and draw more patients to Einstein, and of Dr. Bruce Rapkin will serve to enhance accrual by integrating clinical trials into the spectrum of standard care. In addition, Dr. Perez-Soler was recently awarded a K12 Calabresi grant which will support the recruitment of additional junior medical oncology faculty members engaged in clinical research.

Public Health Relevance

To provide clinical scientific leadership and resources critical for achieving the Eastern Cooperative Oncology Group (ECOG) mission of reducing cancer-related morbidity and mortality by improving the management of early- and advanced-stage carreer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA014958-38
Application #
8303405
Study Section
Subcommittee G - Education (NCI)
Program Officer
Mooney, Margaret M
Project Start
1978-06-01
Project End
2013-04-30
Budget Start
2012-05-01
Budget End
2013-04-30
Support Year
38
Fiscal Year
2012
Total Cost
$101,749
Indirect Cost
$3,298
Name
Albert Einstein College of Medicine
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
110521739
City
Bronx
State
NY
Country
United States
Zip Code
10461
Ignatz-Hoover, James J; Wang, Victoria; Mackowski, Nathan M et al. (2018) Aberrant GSK3? nuclear localization promotes AML growth and drug resistance. Blood Adv 2:2890-2903
Erbe, Amy K; Wang, Wei; Goldberg, Jacob et al. (2017) FCGR Polymorphisms Influence Response to IL2 in Metastatic Renal Cell Carcinoma. Clin Cancer Res 23:2159-2168
Smith, M R; Hong, F; Li, H et al. (2017) Mantle cell lymphoma initial therapy with abbreviated R-CHOP followed by 90Y-ibritumomab tiuxetan: 10-year follow-up of the phase 2 ECOG-ACRIN study E1499. Leukemia 31:517-519
Schneider, Bryan P; Shen, Fei; Jiang, Guanglong et al. (2017) Impact of Genetic Ancestry on Outcomes in ECOG-ACRIN-E5103. JCO Precis Oncol 2017:
Garg, Madhur K; Zhao, Fengmin; Sparano, Joseph A et al. (2017) Cetuximab Plus Chemoradiotherapy in Immunocompetent Patients With Anal Carcinoma: A Phase II Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group Trial (E3205). J Clin Oncol 35:718-726
Sanchez-Martin, Marta; Ambesi-Impiombato, Alberto; Qin, Yue et al. (2017) Synergistic antileukemic therapies in NOTCH1-induced T-ALL. Proc Natl Acad Sci U S A 114:2006-2011
Roberts, Kathryn G; Gu, Zhaohui; Payne-Turner, Debbie et al. (2017) High Frequency and Poor Outcome of Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia in Adults. J Clin Oncol 35:394-401
Perez Horta, Zulmarie; Goldberg, Jacob L; Sondel, Paul M (2016) Anti-GD2 mAbs and next-generation mAb-based agents for cancer therapy. Immunotherapy 8:1097-117
Haas, Naomi B; Manola, Judith; Uzzo, Robert G et al. (2016) Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial. Lancet 387:2008-16
Wilson, Melissa A; Zhao, Fengmin; Khare, Sanika et al. (2016) Copy Number Changes Are Associated with Response to Treatment with Carboplatin, Paclitaxel, and Sorafenib in Melanoma. Clin Cancer Res 22:374-82

Showing the most recent 10 out of 146 publications